



Dr Anthony Mills

Curriculum Vitae

Membership of Professional Organisations

Royal Australasian College of Physicians

Royal College of Pathologists of Australasia

Haematology Society of Australia and New Zealand

- State Councillor 2011-2017; Treasurer 2013-2017

Australasian Leukaemia and Lymphoma Group

- Scientific Advisory Committee 2009-2011
- Safety and Data Monitoring Committee 2012-2021

American Society of Hematology

Australian Medical Association

Publications

Hunt S, Robertson J, Conn J, Casey J, Royle J, Collins J, Hourigan M, Richmond J, Wang T, Mills A and Mason J. A low-dose rituximab regimen for first-line treatment of acquired haemophilia A. *Eur J Haematol*. 2022. 108 (1): 28-33.

Hamad N, Ananda-Rajah M, Gilroy N, MacIntyre R, Gottlieb D, Ritchie D, Harrison S, Kennedy G, Watson A, Greenwood M, Doocey D, Perera T, Spencer A, Wong E, O'Brien T, Shaw P, Conyers R, Milliken S, Bardy P, Larsen S, Ho PJ, Lai H, Bajel A, Butler J, Tiley C, D'Rozario J, Johnston A, Cochrane T, Mills T, Irving I, Pullon H and Purtill D. Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement. *Internal Medicine Journal*. 2021. 51: 1321–1323

Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, Filshie R, Januszewicz H, Joske D, Mills A, Simpson D, Tam C, Taylor K, Watson A, Wolf M and Grigg A. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. *Leukaemia & Lymphoma*. 2019. 60:7, 1796-1802

Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarzer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG). Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. *Leukemia*. 2018 Oct 12. doi: 10.1038/s41375-018-0264-0.

Ross DM, Arthur C, Burbury K, Ko BS, Mills AK, Shortt J, Kostner K. Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors. *Intern Med J*. 2018 Feb;48 Suppl 2:5-13.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarzer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group. Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. *J Clin Oncol*. 2017 May 20;35(15):1678-1685.

Scott A, Morris K, Butler J, Mills AK, Kennedy GA. Treatment of aplastic anaemia with lower-dose anti-thymocyte globulin produces similar response rates and survival as per standard dose anti-thymocyte globulin schedules. *Intern Med J*. 2016 Oct; 46(10):1198-1203.

Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). *Leuk Lymphoma*. 2016 Jun 7:1-10.

Publications (cont)

Ellis M, Mills AK. Successful maintenance of molecular remission in chronic myeloid leukaemia during pregnancy with transition from imatinib to pegylated interferon. *Intern Med J.* 2015 Mar; 45(3):358-9.

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. *Blood.* 2015 Feb 5;125(6):915-23.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goynes JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. *Blood.* 2013 Jul 25;122(4):515-22.

To LB, Levesque JP, Herbert KE, Winkler IG, Bendall LJ, Hiwase DK, Antonenas V, Rice AM, Gottlieb D, Mills AK, Rasko JE, Larsen S, Beligaswatte A, Nilsson SK, Cooney JP, Cambareri AC, Lewis ID. Mobilisation strategies for normal and malignant cells. *Pathology.* 2011 Oct;43(6):547-65.

Herbert KE, Levesque JP, Mills AK, Gottlieb DJ, Cooney J, Szer J, Rasko J, To LB. How we mobilize haemopoietic stem cells. *Intern Med J.* 2011 Aug;41(8):588-94.

Weston H, Cowell V, Grimmett K, Saal R, Jones M, Mills T, Gill D, Marlton P, Bird R, Mollee P. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia. *Intern Med J.* 2011 May;41(5):408-15.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. *Leukemia* 2010; Oct;24(10):1719-24.

Singh S, van Hauten P, Jones K, Grimmett K, Mills AK, Gandhi MK. Selective accumulation of virus specific CD8+ T cells within the peripheral blood stem cell compartment. *Blood.* 2009; 114(9):2001-3.

Keane C, Henden A, Mills T, Wood P. Myeloid and lymphoid neoplasm with FGFR1 abnormality. *Br J Haematol.* 2009; 145(4):440

Hughes TP, Branford S, ...Mills AK et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600mg/day of imatinib as initial therapy. *Blood* 2008; 112(10):3965-73.

Publications (cont)

Morris KL, Tate JR,...Mills AK et al. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. *Int Med J.* 2007; 37(7):456-463

Keane C, Gibbs S ... Mills AK et al. The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. *Hematol Oncol.* 2006 Sep;24(3):159-63.

Gandhi MK, Lambley E,.. Mills T et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. *Clin Cancer Res* 2006; 12(2):460-4.

Tey S.-K., Cobcroft R,.. Mills A et al. A simplified endogenous erythroid colony assay for the investigation of polycythaemia. *Clin Lab Haem* 2004; 26:1-7

Mills AK, Taylor KM, Rodwell RL. Clinical perspectives on cord blood banking. *Transfusion Today* 1999; 38:17-19.

Mills AK, Wright SJ, Taylor KM and McCormack JG. Hypercalcaemia caused by *Pneumocystis Carinii* Pneumonia while in Leukaemic Remission. *Aust NZ J Med* 1999; 29(1):102-3.

Mills AK, Taylor KM, Wright SJ et al. Efficacy, Safety and Tolerability of Anagrelide in the Treatment of Essential Thrombocythaemia. *Aust NZ J Med* 1999; 29(1):29-35.

Rea H, Mills T, Kemp R. Catheter-associated Urinary Tract Infections. *Med J Aust* 1992; 156:813-814.

Presented Abstracts

Yeung D, Grigg A, Shanmuganathan N, Soltenbeck A, White D, Branford S, Viiala N, Rowlings P, Mills A, Shortt J, Tiley C, Ross D, Kipp D, Harrup R, Cunningham I, Kwan J, Eek R, Mutsando H, Tan K, Burbury K, Wright M, Hughes T on behalf of the ALLG. Proactive dasatinib dose reduction in the ALLG CML 12 DIRECT study based on trough levels minimise toxicity and preserve efficacy. EHA2022.

Fox L, Badoux X, Bajel A, Barbaro P, Cole-Sinclair M, Firkin F, Forsyth C, Fox V, Gibson J, Hiwase D, Johnston A, McQuilten Z, Mills A, Morgan S, Opat S, Roncolato F, Ting S, Szer J, Waters N, Zantomio D, Wood E. The Australian Aplastic Anaemia and other Related Bone Marrow Diseases Registry (AAR) – Treatment approaches in and outcomes of the idiopathic aplastic anaemia (iAA) cohort. Blood2021

Fox L, Badoux X, Bajel A, Barbaro P, Cole-Sinclair M, Firkin F, Forsyth C, Fox V, Gibson J, Hiwase D, Johnston A, McQuilten Z, Mills A, Morgan S, Opat S, Roncolato F, Ting S, Szer J, Waters N, Zantomio D, Wood E. The Australian Aplastic Anaemia and other Related Bone Marrow Diseases Registry (AAR) – blood product use in the idiopathic aplastic anaemia (iAA) cohort. Blood2021

Perera N, Yuan Y, Mudie K, Cross D, Van Kuilenburg R, Mills AK, Weber N. A retrospective analysis of the impact VRD induction on peripheral blood stem cell collection for plasma myeloma. Blood2021

McCaughan GJ, Tran S, Durrant S, Harrison SJ, Morton J, Horvath N, Spencer A, Kerridge IH, An Ke Er J, Barge L, Bryant A, Filshie RJ, Choong E, Lai HC, Tiley C, Mills AK, Butler A, Moore J, Hertzberg M, Kennedy GA, Ho PJ, Sidiqi MH, Bashford J, Routledge D, Taylor K, Lee CH, Kalff A, Xia W, and Hamad N. Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. ASH2020

Yeung DT, Grigg A, Shanmuganathan N, Solterbeck A, White D, Branford S, Viiala N, Rowlings P, Mills AK, Shortt J, Tiley C, Ross DM, Kipp D, Harrup RA, Cunningham I, Kwan J, Eek R, Mutsando H, Tan K, Burbury K, Wright M, Hughes TP, on behalf of the ALLG. Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. ASH2019

Yeung DT, Shanmuganathan N, Grigg A, Cunningham I, Shortt J, Rowling P, Reynolds J, Harrup RA, Ross DM, Kipp D, Mills AK, Arthur CK, Schwarzer AP, Jackson K, Viiala N, Weinkove R, Yong AS, White DL, Branford S, Hughes TP, On Behalf of the ALLG. Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study. ASH2019

Presented Abstracts (cont)

Fox L, Firkin F, Badoux X, Bajel A, Cole-Sinclair M, Forsyth C, Gibson J, Hiwase D, Hong F, Johnston A, McQuilten Z, Mills A, Opat S, Roncolato F, Ting S, Szer J, Barbaro P, Fox V, Wellard C, Waters N, Wood E. Update from the Australian Aplastic Anaemia Registry: diagnostic challenges in a diagnosis of exclusion. Blood2019

Winkler IG, Barbier V, Lowe J, Tay J, Magnani JL, Marlton P, Mills AK, Perkins A, Fiveash CE, Erhani JM, Levesque J-P. Vascular E-Selectin Acts As a Gatekeeper Inducing Commitment and Loss of Self-Renewal in HSC Transmigrating through the Marrow Vasculature. ASH2018

Yeung D, Grigg A, Shanmuganathan N, Cunningham I, Shortt J, Rowling P, Reynolds J, Cushion R, Harrap R, Ross DM, Kipp D, Mills AK, Arthur CK, Schwarzer AP, Jackson K, Viiala N, Weinkove R, Yong ASM, White DL, Branford S, Hughes TP. Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study. ASH2018, ASH2017

Jivan Y, Mills A. Aiming for treatment free remission in Chronic myeloid leukaemia. Blood2018

Ross DM, Pagani IS, Shanmuganathan N, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yeung DT, White DL, Grigg AP, Schwarzer AP, Branford S, Hughes TP. Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML). ASH2017

Boyle S, Abro E, Fleser R, Gutta N, Hourigan M, Morton J, Nicol A, Jauch P, Povey M, Van Kuilenberg R, Narayan S, Mills A. Comparison of public versus private autologous stem cell transplantation outcomes for myeloma in Brisbane, Australia. HAA2017

Bradstock K, Link E, Di Iulio J, Szer J, Marlton P, Wei A, Enno A, Schwarzer A, Lewis I, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy M, Hahn U, Cannell P, Tiley C, Lowenthal R, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts A, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour J. Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival. ASH2016

Yeung D, Osborn M, White D, Branford S, Gerber T, Butcher B, Issa S, Hiwase D, Hertzberg M, Gottlieb D, Schwarzer A, Filshie R, Arthur C, Kwan Y, Forsyth C, Taper J, Ross D, Tam C, Mills AK, Grigg A, Hughes T. Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study. ASH2016

Mills A, Knop L, Mapp S, Eliadis P, Morton J, Wisniowski B. Ponatinib facilitates treatment-free remission by inducing deep molecular responses. HAA2016

Presented Abstracts (cont)

Mediwake H, Morris J, Mapp S, Mollee P, Mills A. Outcome of gut rest and total parenteral nutrition in patients undergoing chemotherapy for gastrointestinal tract lymphoma. HAA2016

Hughes T, Mills AK, Cortes J, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini F, Apperley J, Khoury J, Talpaz M, Baccarani M, Lustgarten S, Haluska F, Guilhot F, Deininger M, Hochhaus A, Shah N, Kantarjian H. Long-term Results From the Ponatinib Phase 2 PACE Trial. HAA2016

Scott A, Mills AK, Morris KL, Nakagaki M, Kennedy GA. Low Dose Anti-Thymocyte Globulin (ATGAM) As Treatment of Aplastic Anaemia Is Associated with Similar Response Rates and Survival As per Higher Dose Atgam Schedules. ASH2014

Taylor E, Keane C, Hourigan M, Mills A. The role of gemcitabine based therapy as second-line salvage therapy after failure of platinum-based salvage in aggressive NHL. HAA2014

Ellis M, Mills A. Successful maintenance of molecular remission in CML through pregnancy with transition from imatinib to pegylated interferon. HAA2014

Mills A, Tate J, Jovanovich S, Mollee P, Chiu W, Wienholt L, Gillis D, Reibelt L, Youdell O on behalf of the RCPAQAP Immunochemistry Working Party on Serum Free Light Chains (WP-SFLC). Recommendations for serum free light chains (FLC) measurement in routine laboratories. HAA2014

Sander RL, Nicol A, Mills AK. Acute Glomerulonephritis in the Setting of Haematological Malignancy. HAA2013

Riyat S, McCarthy C, Aung H, Mills T. Atypical MYC and IGH FISH Signal Pattern resulting in IGH/MYC Gene Fusion in a Patient with High-Grade B-Cell Lymphoma. HAA2013

Foster SJ, Mills A, Narayan S, Self M. Use of Plerixafor for HPC. A Mobilisation at PAH. HAA2013

Yeung DT, Osborn MP, White DL, Branford S, Kornhauser M, Slader C, Issa S, Hiwase DK, Hertzberg MS, Schwarzer AP, Filshie R, Arthur CK, Kwan YL, Forsyth CJ, Ross D, Mills AK, Grigg A, Hughes TP on Behalf Of ALLG. Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial. ASH2012

Wilkins S, McQuilten Z, Phillips L, Badoux X, Bajel A, Brown C, Cole C, Corbett G, Cull G, Hiwase D, Gibson J, Johnston A, Mills T, Opat S, Roncolato F, Szer J, Cole-Sinclair M, Wood E, Firkin F. Aplastic anaemia: Establishment of a new international registry. HAA 2012

Presented Abstracts (cont)

Yeung DT, Osborn M, White DL, Branford S, Haswell L, Slader C, Issa S, Hiwase DK, Hertzberg MS, Schwarzer AP, Filshie R, Arthur CK, Kwan YL, Forsyth CJ, Ross DM, Mills AK, Grigg A, Hughes T, and on Behalf Of ALLG. Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial. ASH 2011.

White DL, Saunders V, Frede A, GrootObbink K, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients. ASH2011 and HSANZ 2011.

Yeung D, Osborn M, White D, Branford S, Kornhauser M, Slader C, Hiwase D, Hertzberg M, Schwarzer A, Filshie D, Arthur C, Kwan Y, Forsyth C, Ross D, Mills A, Grigg P, Hughes T. CML patients failing to achieve MMR by 12 months may benefit from dose escalation or switching to nilotinib: A 24 month update of results from the Tidel-II trial. EHA 2011.

Yeung DT, Osborn M, White DL, Branford S, Haswell L, Slader C, Issa S, Hiwase DK, Hertzberg MS, Schwarzer AP, Filshie R, Arthur CK, Kwan YL, Forsyth CJ, Ross DM, Mills AK, Grigg A, Hughes T, and on Behalf Of ALLG. Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial. ASH 2010.

White DL, Saunders V, Frede A, GrootObbink K, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study. ASH 2010.

White DL, Saunders V, Menelaou A, Rofe A, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Imatinib PK: Observations From the TIDEL II Study. ASH 2010 ; HSANZ/HAA2010.

White DL, Saunders V, Frede A, GrootObbink K, Slader C, Branford S, Osborn M, Yeung DT, Mills AK, Grigg A, Hughes T. Imatinib intolerant CML patients respond better to nilotinib than imatinib refractory patients, and this may be due to underlying intrinsic factors: A TIDEL II sub-study. HSANZ/HAA2010.

Kenealy M, Seymour JF,...Mills A et al. The Tolerability of Combination Therapy With Thalidomide and 5-azacitidine in Patients With Advanced Myelodysplastic Syndromes (MDS). ASH 2009.

Osborne M, Branford S,...Mills AK et al. Maintaining imatinib \geq 600 mg daily in the first 12 months of chronic phase CML treatment is associated with superior event-free survival at 5 years. ASH 2009.

Presented Abstracts (cont)

Richmond J, Grimmett K, Mills AK. Peripheral blood CD34 enumeration on patients with very low white cell counts identifies patients with early stem cell mobilisation but may be unnecessary. HSANZ/HAA 2009.

Engelbrecht S, Mills AK, Wellwood J et al. A Case of Concurrent Hodgkin's Lymphoma and Multiple Myeloma Treated with (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) ABVD Chemotherapy and Dexamethasone. HSANZ/HAA 2009.

Mollee P, Tate J,...Mills AK et al. Survival And Prognostic Factors Amongst Australian Patients With AL Amyloidosis. HSANZ/HAA 2009

Narayan S, Mills AK et al. Implementing an Effective HPC-A Collection Efficiency Monitoring System for each Cell Separator. HSANZ/HAA 2009.

Ross DM, Grigg A,...Mills AK et al. The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. ASH2008

Weston H, Kennedy G,...Mills A et al. Outcomes of treatment of adult acute lymphoblastic leukaemia with Hyper-CVAD in Brisbane. HSANZ/HAA 2008.

Szer J, Coyle L,...Mills A et al. Eculizumab for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH): the Australian experience. HSANZ/HAA 2008.

Keane C, Mollee P,...Mills A et al. Oral CID Chemotherapy Followed by Autologous Stem Cell Transplant (ASCT) is an Effective Therapy in the Initial Management of Multiple Myeloma. HSANZ/HAA 2008.

Weston H, Bird R,.. Mills AK et al. JAK2 V617F Mutation Status Predicts Thrombotic Complications, Including Arterial Thrombosis, in Patients with Essential Thrombocythosis (ET). ASH 2007

SL Hall, P Mollee, A Mills et al., Myelodysplasia Due to Copper Deficiency: A Case Report and Review of the Literature. HSANZ 2007.

Lane SW, Saal R... Mills AK et al., Characterisation and Prognostic Significance of *WT-1* Gene Expression in Acute Myeloid Leukemia (AML). ASH 2006

Seymour JF, Grigg A ...Mills AK et al., Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML. ASH 2006.

Middleton HJ, Mollee P...Mills AK et al. Accelerated Delivery of Rituximab Is Safe on an Out-Patient Basis. ASH 2005 and HSANZ 2005.

Presented Abstracts (cont)

Mollee P, Tate J...Mills AK et al. Utility of the Serum Free Light Chain Assay in Patients with AL Amyloidosis. HSANZ 2005.

Mills AK, Gibbs S, ...Marlton P et al. Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen. ASH 2004.

Seymour JF, Grigg AP,.. Mills AK et al. Imatinib's Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML. ASH 2004.

Mollee P, Gibbs S, ... Mills AK et al. Optimal Timing of Peripheral Blood Stem Cell Mobilisation in Patients with Hematological Malignancies Treated with the Hyper-CVAD Chemotherapy Regimen. HSANZ 2004.

Seymour JF, Grigg AP,.. Mills AK et al. A Prospective Analysis of the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than BCR-ABL in Patients with Previously Untreated Early Chronic Phase CML. ASH 2003.

Mollee PN, Mills AK,.. Marlton P et al. The Impact of the Hyper-CVAD Chemotherapy Regimen on the Ability To Mobilize Peripheral Blood Stem Cells (PBSC) in Patients with Hematological Malignancies. ASH 2003

Emmanouilides C, Leonard JP,.. Mills A et al. Multi-Center, Phase 2 Study of Combination Antibody Therapy with Epratuzumab Plus Rituximab in Recurring Low-Grade NHL. ASH 2003.

Taylor KM, Branford S,.. Mills A et al. Imatinib Produces Substantial Molecular Remissions in Interferon-Treated Chronic Phase (CP) Chronic Myeloid Leukemia (CML) in Longstanding

Complete or near Complete Cytogenetic Remission (CCyR) - An Australasian Leukemia and Lymphoma Group (ALLG) Study. ASH 2003

Mills AK, Mollee P, ...Marlton P et al. The Impact of the Hyper-CVAD Chemotherapy Regimen on the Ability to Mobilise Peripheral Blood Stem Cells (PBSC) in Patients with Haematological Malignancies. Annual Scientific Meeting of HSANZ, 2003.

Gandhi MK, Lambley E,.. Mills A et al. Profiling Dynamics of EBV-specific CTL responses in Hodgkin's Disease, and the development of *in-vitro* expansion protocols for LMP-specific CTL. Annual Scientific Meeting of HSANZ, 2003.

Taylor K, Branford S,.. Mills A et al. Imatinib Produces Substantial Molecular Remissions In Interferon Treated Chronic Phase (CP) Chronic Myeloid Leukemia (CML) In Longstanding bcr-abl Positive Cytogenetic Remission (CCR). Annual Scientific Meeting of HSANZ, 2003.

Tey S, Cobcroft R,.. Mills A et al. A Simplified Endogenous Erythroid Colony Assay for the Investigation of Polycythaemia. Annual Scientific Meeting of HSANZ, 2003.

Presented Abstracts (cont)

Mills AK, Kottaridis PD,.. Mackinnon S et al. A non-myeloablative regimen utilising *in-vivo* CAMPATH-1H for allografting patients with Hodgkin's disease: minimal non-relapse mortality and early evidence of a graft-versus-Hodgkin's disease effect. Annual Scientific Meeting of HSA, 2001.

Mills AK, Chakraverty R,.. Mackinnon S et al. Low transplant-related mortality utilising a non-myeloablative conditioning regimen for matched and mismatched unrelated donor stem cell transplants. Annual Scientific meeting of HSA, 2001.

Peggs KS, Mahendra P,.. Mills AK et al. Non-Myeloablative Transplantation Using Matched Unrelated Donors—In-Vivo Campath-1H Limits Graft Versus Host Disease. Blood 2000; 96 (11): Abstract number 3634.

Mills AK, Goldstone AH, Linch DC et al. Long-Term Follow-Up of Allogeneic Bone Marrow Transplants for Lymphoma: The Case for Conventional Conditioning Regimens. Blood 2000; 96 (11): Abstract number 1690.

Mills AK, Taylor KM, Wright SJ et al. for The Australasian Leukaemia and Lymphoma Group. Sustained Responses Following Alternating Chlorodeoxyadenosine (2-CdA) and VAC Regimen in Poor-Risk De-Novo Follicular Non-Hodgkin's Lymphoma. Blood 2000; 96 (11): Abstract number 4778.

Mills AK, Taylor KM, Wright SJ et al. for The Australasian Leukaemia and Lymphoma Group. Poor Yields of Peripheral Blood Stem Cells Following Chlorodeoxyadenosine (2-CdA) and VAC Treatment for Poor-Risk De-Novo Follicular Non-Hodgkin's Lymphoma. Blood 2000; 96 (11): Abstract number 4777.

Rodwell RL, Taylor KM,.. Mills A et al. Development of a cord blood bank. Annual Scientific Meeting, Haematology Society of Australia and New Zealand (HSA), 1999.

Mills AK, Taylor KM, and Wright SJ. Response of Post-Autograft, Relapsed Primary (Thymic) Mediastinal B Cell Lymphoma to Humanised Anti-CD20 Monoclonal Antibody (Rituximab). Blood 1998; 92 (10 suppl 1): Abstract number 4024.

Mills AK, Taylor KM, Wright SJ et al. Efficacy, Safety and Tolerability of Anagrelide in the Treatment of Essential Thrombocythaemia. Annual Scientific Meeting, HSA, 1997 and Advanced Trainees Annual Scientific Meeting, RACP, Queensland Branch, 1998.

Mills AK, Taylor KM, Wright SJ et al. Precursor B-Cell Leukaemia/Lymphoma with Bizarre Morphology, Lytic Bone Lesions and Hypercalcaemia. Annual Scientific Meeting, HSA, 1998.

Clinical Trial Participation - Site Principle Investigator

Myelodysplasia

- A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine with or without MBG453 for the Treatment of Patients with Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
- Phase 1b Dose Escalation Study Evaluating The Safety and Pharmacokinetics of Venetoclax in Combination with Azacitidine in Subjects with Untreated Higher-risk Myelodysplastic Syndromes.
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine with or without Birinapant with a Single Arm Open-Label Run-In Phase in Subjects with Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.
- A Phase 3, Multicenter, Randomized, Double-Blind Study To Compare The Efficacy And Safety Of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Subjects With Red Blood Cell Transfusion Dependent Anemia And Thrombocytopenia Due To IPSS Lower-Risk Myelodysplastic Syndromes.
- A Randomised Phase II study comparing the efficacy of 5azacitidine alone versus combination therapy with Lenalidomide and 5azacitidine in patients with higher risk Myelodysplastic syndromes (MDS) and low marrow blast count acute myeloid leukaemia (AML).
- A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid[®]) Versus Placebo in Subjects with Transfusion-dependent Anemia Due to IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes Without Deletion 5q[31] and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents
- A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS).
- A Multicenter, Randomised, Open-Label, Parallel-group, Phase III Trial of Subcutaneous Azacitidine plus Best Supportive Care versus Conventional Care Regimes plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes. Published as: Feneaux P, Mufti GJ, International Vidaza High-Risk MDS Survival Study Group et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol.* 2009 Mar;10(3):223-32.
- A Phase I/II Trial of Combination Therapy with 5-Azacitidine (Vidaza) and Thalidomide in Patients with Myelodysplastic Syndromes (MDS) - ALLG MDS3.

Chronic lymphocytic leukaemia

- A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

Clinical Trial Participation - Site Principle Investigator (cont)

Chronic Myeloid Leukaemia

- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
- A single arm phase II study to individualize dasatinib dosing based on trough levels and molecular response to maintain efficacy whilst minimising toxicity in elderly patients with chronic myelogenous leukaemia – ALLG CML12.
- Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase CML aiming to maximize CMR and MMR – ALLG CML11
- Phase II of a novel telehealth-mediated nurse-led intervention to increase oral cancer therapy adherence amongst people with Chronic Myeloid Leukaemia (CML) – REMIND; ALLG SC04
- Extending Molecular Responses With Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase - ENESTxtnd
- Response Post Tyrosine Kinase Inhibitor: Assessment of Sensitivity and Therapeutic Response to Next-Line Therapy in CML: The Australasian RESIST Study – ALLG CML10
- A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
- An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients with Evidence of Persistent Leukemia by RQ-PCR - ENESTcmr
- A Phase II Study of Withdrawal of Imatinib Therapy in Adult Patients with Chronic Phase Chronic Myeloid Leukaemia in Stable Complete Molecular Remission - ALLG CML8.
- A Phase II study in adult patients with newly diagnosed chronic-phase chronic myeloid leukaemia of initial intensified imatinib therapy and sequential dose escalation followed by treatment with nilotinib in suboptimal responders to determine the rate and duration of major molecular response – ALLG CML9.
- A Randomized Open-Label Study of 400mg versus 800mg of Gleevec/Glivec (Imatinib Mesylate) in Patients with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints - TOPS.
- Phase II trial of Pegasys in Glivec-responsive chronic myeloid leukaemia – ALLG CML7.
- A phase II study in adult patients with newly-diagnosed chronic myeloid leukaemia of initial intensified Glivec therapy and sequential therapy for non-responders – ALLG CML6.

Myeloma

- An open-label, 3-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of elranatamab (pf-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor.
- A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy.

Lymphoma

- A phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab plus Lenalidomide in Addition to R-CHOP versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients with Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
- Lymphoma Working Party Randomised Study of Rituximab (MabThera) in Patients with Relapsed or Resistant Follicular Lymphoma Prior to High Dose Therapy as In Vivo Purging and to Maintain Remission Following High Dose Therapy
- A phase II study of idarubicin-based combined modality therapy in primary central nervous system lymphoma – ALLG LY03.
- A prospective, non-randomised study of chemotherapy and radiotherapy for osteolymphoma – ALLG LY02.
- A Randomised Multicentre Trial Of Involved Field Radiotherapy Versus Involved Field Radiotherapy Plus Chemotherapy In Combination With Rituximab (Mabthera) For Stage I - II Low Grade Follicular Lymphoma – ALLG NHLLOW5
- A multicenter phase III randomized double-blind placebo-controlled study to evaluate the efficacy of two dose levels of DAB₃₈₉IL-2 (9 and 18 mg/kg/day) in cutaneous T-cell lymphoma (CTCL) patients with Stage Ia-III disease who, following ≥3 previous therapies, have recurrent or persistent disease that has been biopsy-documented to express CD25
- A phase 2 clinical trial testing AMG 412 in combination with rituximab in subjects with refractory or recurrent low-grade, CD20+ B-cell non-Hodgkin's lymphoma

Paroxysmal Nocturnal Haemoglobinuria

- ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
- Dose-Escalation Study of ALXN1210 IV in Patients With PNH
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Eculizumab in Subjects with Hemolytic Paroxysmal Nocturnal Hemoglobinuria
- PNH Registry

Immune thrombocytopenia

- A Retrospective, Observational Study of Patients with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) to determine Standard of Care (SOC) in Australia.

Aplastic Anaemia

- Aplastic anaemia registry
- Avatrombopag plus upfront immunosuppressive therapy in treatment-naive severe aplastic anaemia - The DIAAMOND Ava-FIRST Trial; Avatrombopag in relapsed or refractory severe aplastic anaemia as extra Therapy – The DIAAMOND Ava-NEXT Trial